CHRONULAC
LOE ApproachingNDAORALSOLUTION
Approved
Jun 1979
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CHRONULAC is an oral solution small-molecule product approved in 1979 by Sanofi for gastrointestinal indications. The specific mechanism of action and therapeutic indication are not publicly detailed in available data, but the product has maintained market presence for over 40 years. It is formulated as an oral solution designed for chronic or symptomatic management.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30%), indicating defensive commercial strategy and reduced team expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CHRONULAC offers limited career growth as the product enters LOE with minimal linked job openings. Roles focus on defending market share, managing generic competition, and operational efficiency rather than innovation or expansion.
Brand ManagerField Sales Representative
Worked on CHRONULAC at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.